REZDIFFRA (resmetirom) tablets
REZDIFFRA (resmetirom) – MASH, formerly NASH Therapy in India
Rezdiffra (resmetirom) is the first FDA-approved medication for adults with metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) who have moderate to advanced liver scarring (fibrosis), used alongside diet and exercise to reduce liver fat, inflammation, and scarring by targeting liver thyroid hormone receptors. It’s an oral tablet taken once daily and works as a liver-directed therapy, though potential side effects include diarrhea, nausea, itching, and gallbladder issues, with ongoing studies confirming its long-term benefits.
| Brand Name: | REZDIFFRA |
| Generic Name: | Resmetirom Tablets |
| Strength: | • Tablets: 60 mg, 80 mg, and 100 mg |
| Manufacturer: | Madrigal Pharmaceuticals |
| Approved By: | EMA, USFDA |
Source Details: Patient Information.
REZDIFFRA must always be used under the supervision of a Registered Medical Practitioner (RMP).
Access REZDIFFRA for MASH, formerly NASH on a Named Patient Import Basis
IPN, New Delhi serves as a facilitator for the procurement of specialized drugs on behalf of patients or treating doctors, enabling access to REZDIFFRA (resmetirom) tablets for personal use. To proceed, the applicant must submit an application in Form 12A along with a valid prescription issued by a Registered Medical Practitioner (RMP).
For any queries, including information regarding the cost of the pharmaceutical product in India, please contact the IPN Healthcare Support Team via email or at the following numbers: Mobile/WhatsApp: Mr. Tarun: +91 9891 296 838 | Mr. Neeraj: +91 9811 747 774.
Note: All access is provided strictly on a Named Patient Import Basis and for personal use only, in accordance with Indian regulatory guidelines.
Contact Info
CORPORATE OFFICE:
Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.
MOBILE / PHONE NUMBER:
M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398
EMAIL ID:
Resmetirom, sold under the brand name Rezdiffra, is a medication used to treat a form of fatty liver disease. Specifically it is used in the treatment of noncirrhotic metabolic dysfunction associated steatohepatitis (MASH) (formerly known as nonalcoholic steatohepatitis NASH). It is structurally similar to the thyroid hormone triiodothyronine and acts as an agonist of the thyroid hormone receptor beta (NR1A2).
The most common side effects include diarrhea and nausea.
NASH is a result of the progression of nonalcoholic fatty liver disease where liver inflammation, over time, can lead to liver scarring and liver dysfunction. NASH is often associated with other health problems such as high blood pressure and type 2 diabetes. By at least one estimate, approximately 6-8 million people in the U.S. have NASH with moderate to advanced liver scarring, with that number expected to increase. Rezdiffra is a partial activator of a thyroid hormone receptor; activation of this receptor by Rezdiffra in the liver reduces liver fat accumulation.
Contact IPN – REZDIFFRA Access in India
For inquiries regarding availability, import process, or cost of REZDIFFRA (resmetirom):
India Pharma Network (IPN) : Headquartered in New Delhi, with branch offices in Delhi, Gurugram, Mumbai, Bangalore, Kolkata, Chennai, Pune, Ahmedabad, Hyderabad, Chandigarh, Jaipur and Lucknow, IPN supports medicine imports across India on a Named Patient Import Basis and for personal use only. Mobile/WhatsApp: Mr. Tarun: +91 9891 296 838 | Mr. Neeraj: +91 9811 747 774. Email: info@indianpharmanetwork.co.in
NEWS/UPDATES
- FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease.
- Madrigal Pharmaceuticals Announces FDA Patent Allowance for Rezdiffra™ Providing Protection Through September 2044.
- FDA Approves First Drug for MASH.
Compliance & Disclaimer
India Pharma Network acts solely as a facilitator for REZDIFFRA (resmetirom) access. IPN does not manufacture, sell, or promote medicines and does not provide medical advice. All imports are:
- Strictly on a Named Patient Import Basis
- Exclusively for personal use
- Not for resale, distribution, or commercial sale
- Subject to applicable Indian laws and regulatory approvals
The prescribing physician remains solely responsible for dosage, therapy, and clinical decisions.
Indian Pharma Network (IPN), New Delhi. India
Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa
Mobile / WhatsApp / Phone
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398
Free Customer Support
info@indianpharmanetwork.co.in
urgent@indianpharmanetwork.co.in